News
Application Note│Comprehensive Profiling of Approved Anti-CD20 mAbs Using Fc Effector Function Platform
Summary CD20 is a key target for treating B-cell malignancies, enabling selective B-cell depletion. This study compared Rituximab (RTX), Ofatumumab (OFA), and Obinutuzumab (OBZ), revealing distinct profiles of known and previously unreported Fc-effector functions,...
SeromYx Systems and ACROBiosystems Announces Strategic Collaboration on Comprehensive Functional Profiling of Anti-CD20 Monoclonal Antibodies
Download PDFWoburn, MA / Newark, DE – October 1st, 2024 - SeromYx Systems, a cutting-edge immunology technology company, and ACROBiosystems, a leading provider for life science solutions and tools, are excited to announce the release of their joint study on the...
SeromYx Systems Announces Strategic Collaboration to Advance Understanding and Treatment of Long COVID
Download PDFWoburn, MA, September, 25th, 2024 – SeromYx Systems, a leading provider of GCLP Systems Serology and Antibody characterization services, is excited to announce a new immunobiology collaboration to better understand Post-Acute Sequelae of SARS-CoV-2...
White Paper │ View from the Fc: 5 Rules for mAb Development Risk Reduction
Designing monoclonal antibodies and related modalities such as ADCs and bispecifics with appropriate Fc function is critical to product safety and efficacy, but fiendishly hard. Outcomes are contextual, meaning that what works in one disease state/epitope setting may...
